Trials / Terminated
TerminatedNCT05516758
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 491 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.
Conditions
- Rheumatoid Arthritis
- Arthritis
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peresolimab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2022-08-31
- Primary completion
- 2023-11-20
- Completion
- 2025-01-17
- First posted
- 2022-08-26
- Last updated
- 2025-12-04
- Results posted
- 2025-12-04
Locations
131 sites across 11 countries: United States, Argentina, Canada, China, Greece, Hungary, Japan, Mexico, Poland, Puerto Rico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05516758. Inclusion in this directory is not an endorsement.